Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Open accessThe DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Abstract
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. However, therapeutic approaches aimed at decreasing Aβ levels have so far failed, and tau-based clinical trials have not yet produced positive findings. This begs the question of whether the hypothesis is correct. Here we have examined literature on the role of Aβ and tau in synaptic dysfunction, memory loss, and seeding and spreading of AD, highlighting important parallelisms between the two proteins in all of these phenomena. We discuss novel findings showing binding of both Aβ and tau oligomers to amyloid-β protein precursor (AβPP), and the requirement for the presence of this protein for both Aβ and tau to enter neurons and induce abnormal synaptic function and memory. Most importantly, we propose a novel view of AD pathogenesis in which extracellular oligomers of Aβ and tau act in parallel and upstream of AβPP. Such a view will call for a reconsideration of therapeutic approaches directed against Aβ and tau, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRx0237 (21, LMTX) is a tau aggregation inhibitor.465”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [465]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Also, tau pathology is likely to begin in EC then move to the hippocampus, and ultimately invading the cortex, following an overlapping path existing among functionally connected areas [55, 157, 158, 177].”
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 3×
“Unfortunately, while the “Oligomer Hypothesis” is still a matter of investigation, and data are being gathered to test the grounds of its premises, the clinical failure of most of the anti-A (cid:2) drugs has strongly destabilized this concept.”
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Second, we know since the 1990 s that there is no correlation between A (cid:2) deposition and clinical degree of dementia among affected individuals [25–28], and plaques might occur in the brains of individuals with no sign of dementia [27, 29, 30].”
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“This was predicted by a study showing that all of the soluble oligomers tested including β-synuclein, islet amyloid polypeptide, polyglutamine, lysozyme, human insulin, and prion peptide 106–126, display a common conformation-dependent structure that is unique to soluble oligomers [193], By now, a variety of studies h…”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“This temporal sequence derives from studies in patients with FAD, where the genetic-driven increase of Aβ is followed by NFT accumulation [194], whereas the increase of tau, as in tauopathies, is not associated with Aβ deposition.”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Cited by
Items 301–314 of 314
Bhattacharya, H., Chakraborty, P., & Dewanjee, S. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.022
Chen, M., Zuo, C., Li, R., Zhang, J., Yao, Z., Li, L., & Cheng, L. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00314-0
“For decades, research has centered on the amyloid cascade hypothesis and tau pathology as primary drivers of neurodegeneration [5, 6].”
Adhikari, S., Carlyle, B. C., & de Wet, H. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100057
Murthy, M. K. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111921
Profiling proteome-level amino acid substitutions in Alzheimer’s disease brain tissuePreprint
Zhao, P., Lai, S., Dai, S., Zhou, C., Li, N., & Yu, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.08.750259
Epigenetic control of transposable elements in brain and brain disorders
Smith, C. A., & Hamilton, P. J. (2026) · Epigenetics · doi:10.1080/15592294.2026.2732514
“Alzheimer’s disease (AD) is a common form of dementia, and two of the neuropathological hallmarks of AD are accumulation of hyperphosphorylated microtubule-associated protein tau and of amyloid-β protein plaques [152].”
A silent RAGE: The inflammatory pathway to dementia in Parkinson’s disease
Peixoto, D. O., Gasparotto, J., Ojo, O. R., Aro, O. P., Godswill, U.-A. S., de Abreu, L. F., Lopes, L. C., Moreira, J. C. F., & Gelain, D. P. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103392
Astrocytic timekeepers and their influence on brain waste clearance in Alzheimer's disease
Koenders, C. L., Chiu, R. K., Medeiros-Furquim, T., & Bergink, S. (2026) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2026.100155
“However, only tau pathology was mitigated and tau pathology is thought to be downstream of A β 42 accumulation (Aksman et al., 2023; Bloom, 2014; Gulisano et al., 2018).”
Abdelaziz, G., Abdel-Ghaffar, A.-R. B., Amr, D., Nada, A. M. K., & Gabre, R. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-71629-5
“The observed reduction in amyloid-β (Aβ) and tau burden suggests that both dietary interventions influence upstream pathogenic processes, potentially including amyloid precursor protein processing, tau kinase activity, and protein clearance pathways 25 .”
PDE4D-targeted Small Molecules from Computational Screening for Dementia
Ma, S. (2026) · European Journal of Biomedical and Life Sciences · doi:10.29013/ejbls-26-2.3-66-85
Khan, M. A., Chinnappan, R., Andole, S., Akif, M., Mir, T. A., Yaqinuddin, A., Pham, P.-T. T., & Bader, M. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209355
“…hallmark of Alzheimer’s disease is the abnormal deposition of amyloid-β (A β ) peptides in the extracellular space, together with the intracellular accumulation of aberrantly phosphorylated tau protein, giving rise to amyloid plaques and neurofibrillary tangles (NFTs), respectively [2,3].”
Gupta, J., Toppo, P., Akbar, M., Vishwakarma, A., Somabattini, R. A., Nanjappan, S. K., Nazir, A., & Sashidhara, K. V. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122570
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
BindingDB Entry 50015539: Histamine H
BindingDB (2023) · UC San Diego · doi:10.7270/q2dr30df
Metadata
- Authors
- Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., Puzzo, D., & Arancio, O.
- Affiliations
- University of Catania (IT)
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
- Columbia University (US)
- Università Cattolica del Sacro Cuore (IT)
- Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
- Corresponding author
- Puzzo, Daniela
- Arancio, Ottavio
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S611-S631
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8371153
- OpenAlex
- W2807540667
- Cited by
- 313
- References
- 223
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 60 · 2023: 32 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- Funders
- National Institute on Aging (R01AG049402, R01AG017761)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Humans, Signal Transduction, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.